In PDX models, HDAC3 inhibition with BRD3308 reduced tumor growth, and induced upregulation of BCL6 target genes and MHC-II expression in the setting of both CREBBP-mutant and CREBBP-WT diseases (Mondello et al., 2020). Here, BCL6 is linked to neoplasm.